InvestorsHub on MSN
Johnson & Johnson presents three-year TREMFYA data showing sustained ulcerative colitis outcomes
Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to ...
The chronic autoimmune conditions — both considered types of inflammatory bowel disease — cause a myriad of symptoms ...
An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...
Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Everyday Health on MSN
Crohn’s disease versus ulcerative colitis: What’s the difference?
Crohn’s and UC affect the GI tract differently. Crohn’s impacts the whole tract, while UC is limited to the colon. Learn the ...
Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.
There’s no single best exercise for UC, but yoga may reduce stress and improve quality of life. Adjust intensity and exercise ...
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). It causes painful sores and inflammation deep inside your colon and rectum. That can lead to hard-to-manage symptoms like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results